Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 236

1.

Measuring the quality of outpatient treatment for schizophrenia.

Young AS, Sullivan G, Burnam MA, Brook RH.

Arch Gen Psychiatry. 1998 Jul;55(7):611-7.

PMID:
9672051
2.

Patient, provider, and treatment factors associated with poor-quality care for schizophrenia.

Young AS, Sullivan G, Duan N.

Ment Health Serv Res. 1999 Dec;1(4):201-11.

PMID:
11256726
3.

Benchmarking treatment of schizophrenia: a comparison of service delivery by the national government and by state and local providers.

Rosenheck RA, Desai R, Steinwachs D, Lehman A.

J Nerv Ment Dis. 2000 Apr;188(4):209-16.

PMID:
10789997
4.

Improving outpatient treatment in schizophrenia: effects of computerized guideline implementation--results of a multicenter-study within the German research network on schizophrenia.

Janssen B, Ludwig S, Eustermann H, Menke R, Haerter M, Berger M, Adam G, Seemann U, Kissling W, Gaebel W.

Eur Arch Psychiatry Clin Neurosci. 2010 Feb;260(1):51-7. doi: 10.1007/s00406-009-0016-2. Epub 2009 May 12.

PMID:
19876665
5.
6.

Guideline recommendations for treatment of schizophrenia: the impact of managed care.

Dickey B, Normand SL, Hermann RC, Eisen SV, Cortes DE, Cleary PD, Ware N.

Arch Gen Psychiatry. 2003 Apr;60(4):340-8.

PMID:
12695310
9.

How well does chart abstraction measure quality? A prospective comparison of standardized patients with the medical record.

Luck J, Peabody JW, Dresselhaus TR, Lee M, Glassman P.

Am J Med. 2000 Jun 1;108(8):642-9.

PMID:
10856412
10.

Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.

Loosbrock DL, Zhao Z, Johnstone BM, Morris LS.

J Ment Health Policy Econ. 2003 Jun;6(2):67-75.

PMID:
14578539
11.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

12.
13.

The Canadian National Outcomes Measurement Study in Schizophrenia: overview of the patient sample and methodology.

Smith G, Malla A, Williams R, Kopala L, Love L, Balshaw R.

Acta Psychiatr Scand Suppl. 2006;(430):4-11.

PMID:
16542320
14.

[Caregiver burden in relatives of persons with schizophrenia: an overview of measure instruments].

Reine G, Lancon C, Simeoni MC, Duplan S, Auquier P.

Encephale. 2003 Mar-Apr;29(2):137-47. Review. French.

PMID:
14567165
15.
16.
17.

[Schizophrenia diagnostic announcement in a French psychiatric unit].

Rocamora JF, Benadhira R, Saba G, Stamatadis L, Kalalaou K, Dumortier G, Plaze M, Aubriot-Delmas B, Glikman J, Januel D.

Encephale. 2005 Jul-Aug;31(4 Pt 1):449-55. French.

PMID:
16389712
18.

Electronic health record use and the quality of ambulatory care in the United States.

Linder JA, Ma J, Bates DW, Middleton B, Stafford RS.

Arch Intern Med. 2007 Jul 9;167(13):1400-5.

PMID:
17620534
19.

Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior.

Hogarty GE, Flesher S, Ulrich R, Carter M, Greenwald D, Pogue-Geile M, Kechavan M, Cooley S, DiBarry AL, Garrett A, Parepally H, Zoretich R.

Arch Gen Psychiatry. 2004 Sep;61(9):866-76.

PMID:
15351765
20.

The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression.

Katon WJ, Von Korff M, Lin EH, Simon G, Ludman E, Russo J, Ciechanowski P, Walker E, Bush T.

Arch Gen Psychiatry. 2004 Oct;61(10):1042-9.

PMID:
15466678

Supplemental Content

Support Center